Silence Therapeutics plc ( SLN) - Key Metrics
SLN Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0 | -$0.26 | $0.03 | $0.03 |
| 2026Q1 | $0.01 | -$0.32 | -$0.33 | -$0.33 |
| 2025Q4 | $0 | -$0.25 | -$0.37 | -$0.37 |
| 2025Q3 | $0.01 | -$1.33 | -$0.69 | -$0.69 |
| 2025Q2 | $0.02 | -$2.38 | -$1.38 | -$1.39 |
SLN Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -10.17 |
| 2026Q1 | 0% | -3.99 |
| 2025Q4 | 0% | -5.63 |
| 2025Q3 | 0% | -0.98 |
| 2025Q2 | 0% | -0.60 |
SLN Free Cash Flow Yield and Dividend Yield
| Date | Free Cash Flow Yield | Dividend Yield |
|---|---|---|
| 2026Q2 | 0.29% | 0% |
| 2026Q1 | -6.27% | 0% |
| 2025Q4 | -6.04% | 0% |
| 2025Q3 | -13.33% | 0% |
| 2025Q2 | -23.91% | 0% |
SLN
Price: $13.72
52 week price:
Earnings Per Share: -1.19 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United Kingdom
Volume: 18800
Market Capitalization: 641.4 million